Canagliflozin Ups Survival in Type 2 Diabetes With Macroalbuminuria

SAN DIEGO—Canagliflozin treatment is associated with improved survival and cardiovascular outcomes in patients with type 2 diabetes and macroalbuminuria, according to study findings presented at the American Society of Nephrology’s Kidney Week 2018 conference.

The findings are from a study of 760 participants in the CANVAS (Canagliflozin Cardiovascular Assessment Study) Program who had type 2 diabetes, macroalbuminuria (urinary albumin:creatinine ratio [UACR] greater than 300 mg/g), and a history or high risk of cardiovascular disease. At enrollment, the study cohort had a mean age of 64 years, hemoglobin A1c of 8.5%, and estimated glomerular filtration rate (eGFR) of 66 mL/min/1.73 m² and a median UACR of 722 mg/g. Investigators had randomly assigned patients receive canagliflozin or placebo.

Compared with placebo recipients, canagliflozin-treated patients experienced a 36% decrease in UACR from baseline to the end of follow-up, Vlado Perkovic, MD, of the George Institute for Global Health and the University of New South Wales in Australia, and colleagues reported. The canagliflozin group also had a slower chronic annual decline in eGFR than the placebo group (˗1.76 vs ˗4.77 mL/min/1.73 m²).

In addition, compared with placebo, canagliflozin was associated with a significant 42% decreased risk of a composite outcome of a 40% decrease in eGFR, end-stage renal disease, or renal death, as well as a significant 37% decrease in all-cause mortality.

Reference

Perkovic V, Li Q, Jardin MJ, et al. Canaglilozin in patients with type 2 diabetes and macroalbuminuria: Data from the CANVAS Program. Data presented at the American Society of Nephrology’s 2018 Kidney Week conference in San Diego, Oct. 23-28. Abstract TH-OR039.